Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Apogee Therapeutics, Inc.NASDAQ: APGE
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses growth accelerates
Q2 FY2026 other income / expenses of $10.23M rose 43.2% year over year, ahead of the +2.1% change in trailing-twelve-month other income / expenses. Sequentially, it rose 17.0% from the prior quarter.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +43.2% holds above the trailing-twelve-month pace of +2.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 30.03M USD
- Year-over-year change
- -13.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.03M | -13.6% |
| FY2024 | 2024-12-31 | 34.74M | +285.3% |
| FY2023 | 2023-12-31 | 9.02M | +199.6% |
| FY2022 | 2022-12-31 | (9.06M) | — |
Other Income / Expenses vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2.1% is the 6th highest of 10, against a peer median of +9.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $73.27M USD | +112.8% | — | 16.3% | |
| LTM Sep 2026 | $35.81M USD | +15.2% | +93.5% | — | |
| LTM Jun 2026 | $34.02M USD | +2.1% | — | — | |
| LTM Sep 2026 | $27.28M USD | -4.7% | — | 442.4% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $22.95M USD | +0.0% | +234.3% | — |
| LTM Mar 2026 | $7.32M USD | +130.1% | — | — | |
| LTM Sep 2026 | -$1.9M USD | +94.1% | — | 0.1% | |
| LTM Jun 2026 | -$17.81M USD | -757.0% | — | — | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥23.21M CNY | +9.1% | — | 4.2% |
| LTM Mar 2026 | -$43.77M USD | -30.4% | — | 6.5% | |
| Peer median (excluding APGE) | — | +9.1% | +163.9% | 6.5% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.42M |
| Gross Profit | 0 | 0 | 0 | (1.42M) |
| Gross Margin | — | — | — | — |
| Research & Development | 27.79M | 68.42M | 167.87M | 214.71M |
| Selling, General & Admin | 2.94M | 24.58M | 49.01M | 70.88M |
| Operating Expenses | 30.73M | 93M | 216.87M | 284.18M |
| Depreciation & Amortization | 0 | 9.02M | 189K | 1.42M |
| EBITDA | (39.79M) | (74.97M) | (181.94M) | (254.15M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (30.73M) | (93M) | (216.87M) | (285.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 92K | 9.02M | 34.74M | 30.03M |
| Interest Expense | 9.15M | 0 | 0 | 0 |
| Other Income / Expenses | (9.06M) | 9.02M | 34.74M | 30.03M |
| Income Before Tax | (39.79M) | (83.99M) | (182.13M) | (255.57M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 18K | 278K |
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.79) | (1.66) | (3.30) | (4.22) |
| EPS (Diluted) | (0.79) | (1.66) | (3.30) | (4.22) |
| Weighted Avg Shares | 50.67M | 50.66M | 55.19M | 60.69M |
| Weighted Avg Shares (Diluted) | 50.67M | 50.66M | 55.19M | 60.69M |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.